

Elaine M Walsh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7157543/publications.pdf>

Version: 2024-02-01

27
papers

342
citations

1163065

8
h-index

888047

17
g-index

27
all docs

27
docs citations

27
times ranked

741
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of inducible nitric oxide synthase (iNOS) expression on triple negative breast cancer outcome and activation of EGFR and ERK signaling pathways. <i>Oncotarget</i> , 2017, 8, 80568-80588.	1.8	61
2	Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study. <i>Cancers</i> , 2019, 11, 995.	3.7	53
3	Review of Triple Negative Breast Cancer and the Impact of Inducible Nitric Oxide Synthase on Tumor Biology and Patient Outcomes. <i>Critical Reviews in Oncogenesis</i> , 2016, 21, 333-351.	0.4	44
4	Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review. <i>Clinical Sarcoma Research</i> , 2015, 5, 17.	2.3	39
5	Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 1-9.	2.5	37
6	Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 573-582.	2.5	27
7	Management of hormone receptor-positive, HER2-negative early breast cancer. <i>Seminars in Oncology</i> , 2020, 47, 187-200.	2.2	24
8	Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 1-13.	2.5	21
9	Single agent anti PD-1 inhibitors in esophageal cancerâ€”a first step in a new therapeutic direction. <i>Journal of Thoracic Disease</i> , 2018, 10, 1308-1313.	1.4	7
10	Extended Endocrine Therapy for Early-Stage Breast Cancer: How Do We Decide?. <i>Current Oncology Reports</i> , 2020, 22, 123.	4.0	6
11	Effect of delays in initiation of adjuvant endocrine therapy on survival among women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 965-975.	2.5	6
12	Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. <i>Clinical Breast Cancer</i> , 2021, , .	2.4	6
13	Is chemotherapy always required for cancer in pregnancy? An observational study. <i>Irish Journal of Medical Science</i> , 2017, 186, 875-881.	1.5	4
14	Breast cancer detection among Irish BRCA1 & BRCA2 mutation carriers: a population-based study. <i>Irish Journal of Medical Science</i> , 2016, 185, 189-194.	1.5	3
15	FOLFIRINOX in pancreatic cancer: Can results be reproduced outside the clinical trial setting?. <i>Journal of Clinical Oncology</i> , 2014, 32, e15236-e15236.	1.6	2
16	Molecular Tumor Board Guides Successful Treatment of a Rare, Locally Aggressive, Uterine Mesenchymal Neoplasm. <i>JCO Precision Oncology</i> , 2021, 5, 333-339.	3.0	1
17	Breast cancer detection among Irish BRCA1 and BRCA2 mutation carriers.. <i>Journal of Clinical Oncology</i> , 2012, 30, e12038-e12038.	1.6	1
18	Nitric Oxide and Nitric Oxide Donors in Preclinical Studies of Breast and Prostate Cancer. , 2017, , 57-70.		0

#	ARTICLE	IF	CITATIONS
19	Journal Watch: our experts look back and highlight some of the key breast cancer research articles from 2018. Breast Cancer Management, 2018, 7, BMT19.	0.2	0
20	Breast cancer detection among Irish BRCA1 and BRCA2 mutation carriers.. Journal of Clinical Oncology, 2012, 30, 59-59.	1.6	0
21	Cancer in pregnancy: To treat or not?. Journal of Clinical Oncology, 2013, 31, e12533-e12533.	1.6	0
22	Switching chemotherapy in adult osteosarcoma patients with poor necrosis rates post neoadjuvant methotrexate, cisplatin, and doxorubicin (MAP).. Journal of Clinical Oncology, 2013, 31, 10530-10530.	1.6	0
23	Post-therapy fibrosis as a surrogate of original tumor bulk in locally advanced rectal cancer (LARA): An exploratory study of radiographic mis-staging and inflation of therapeutic benefit.. Journal of Clinical Oncology, 2014, 32, e14551-e14551.	1.6	0
24	Abstract 1708: Identification of triple negative breast cancer (TNBC) subtypes by an immunohistochemistry (IHC) panel with impact on clinical outcomes. , 2015, , .		0
25	Abstract P6-05-09: Subtyping of triple negative breast cancer by a novel immunohistochemistry panel: Assessing the correlation between subtypes and clinical outcomes. , 2016, , .		0
26	Abstract P2-05-15: NOS2&COX2 activation of TLR4 & EGFR signalling causes poor outcome in oestrogen receptor-negative breast cancer via pro-survival signals and immune polarisation. , 2016, , .		0
27	The role of stromal tumor infiltrating lymphocytes (sTILs) as a predictive biomarker for carboplatin-based neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2019, 37, e12085-e12085.	1.6	0